BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions
Data support development of next-generation APJ agonists for obesity and key comorbidities
EMERYVILLE, Calif., June 21, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) ('BioAge', 'the Company'), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that it will present new preclinical data supporting apelin receptor (APJ) agonism for the treatment of diabetic obesity and heart failure with preserved ejection fraction (HFpEF). The data will be presented at the American Diabetes Association's 85th Scientific Sessions, held June 20–23, 2025, in Chicago, Illinois.
'Our preclinical data demonstrated that APJ activation can confer multiple benefits in models of diabetic obesity and heart failure, and enhance the effects of incretin therapy,' said Kristen Fortney, PhD, CEO and co‑founder of BioAge. 'We are advancing next‑generation APJ agonists to translate this promising biology into new therapies for obesity and its major comorbidities.'
APJ is the receptor for apelin, an exercise-induced signaling molecule known as an exerkine. Apelin has been shown in preclinical studies to have the potential to recapitulate many of the downstream benefits of exercise. BioAge's discovery platform identified apelin signaling as a therapeutic target based on analysis of human aging cohorts, which revealed that higher levels of circulating apelin are predictive of improved physical function and increased longevity. BioAge has shown that in preclinical obesity models, APJ agonism can approximately double the weight loss induced by GLP-1 receptor agonists while restoring body composition and muscle function, suggesting that APJ agonists could serve as pharmacological exercise mimetics to enhance incretin therapy.
BioAge is advancing multiple APJ agonist approaches, including both oral small-molecule and long-acting injectable formulations, with an IND filing targeted for 2026 [ link ].
In their two presentations, BioAge CMO and EVP Research Paul Rubin, MD, and scientist Shijun Yan, PhD, MBA, will present data that demonstrated that in preclinical models of diabetic obesity and HFpEF, APJ agonist treatment had potential as monotherapy that could be enhanced in combination with incretin therapies.
Oral presentation: Saturday Jun 21, 2025 5:00 PM - 5:15 PM CDT
Title: An Oral Apelin Receptor Agonist Enhances Glycemic Control in Preclinical Models of Diabetic Obesity Both as Monotherapy and in Combination with Tirzepatide
Session: Early Phase, Post Hoc, and Subgroup Analyses from Clinical Trials Testing Incretin-Based Therapies—Take 1; W181 A-C
Presenter: Paul Rubin, MD, Chief Medical Officer and EVP-Research
Poster presentation: Sunday Jun 22, 2025 12:30 PM - 1:30 PM CDT
Title: The Apelin Receptor Agonist Azelaprag Shows Cardioprotective Effects as Monotherapy and Enhanced Benefits with Semaglutide in a Diet-Induced Obesity Model of Heart Failure with Preserved Ejection Fraction
Session: Poster Hall F1, Board No. 866
Presenter: Shijun Yan, PhD, MBA, Senior Scientist, In Vivo Biology
The visual materials for the presentations will be made available on the BioAge investor website https://ir.bioagelabs.com concurrent with the beginning of their respective sessions.
About BioAge Labs, Inc.
BioAge is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The Company's lead product candidate, BGE-102, is a potent, orally available, brain-penetrant small-molecule NLRP3 inhibitor being developed for obesity. BGE-102 has demonstrated significant weight loss in preclinical models both as monotherapy and in combination with GLP-1 receptor agonists. IND submission and initiation of a Phase 1 SAD/MAD trial are planned for mid-2025, with initial SAD data anticipated by end of year. The Company is also developing long-acting injectable and oral small molecule APJ agonists for obesity. BioAge's additional preclinical programs, which leverage insights from the Company's proprietary discovery platform built on human longevity data, address key pathways involved in metabolic aging.
Forward-looking statements
This press release contains 'forward-looking statements' within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding our plans to develop and commercialize our product candidates, including BGE-102 and our APJ program, the timing and results of our planned clinical trials, risks associated with clinical trials, including our ability to adequately manage clinical activities, the timing of our IND filing for BGE-102 or our APJ program, our ability to obtain and maintain regulatory approvals, the clinical utility of our product candidates or their ultimate ability to treat human disease, the expected timeline for completing proteomic analysis, anticipated analytical results and the potential for identifying novel therapeutic targets, and general economic, industry and market conditions. These forward-looking statements may be accompanied by such words as 'aim,' 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,' 'forecast,' 'goal,' 'intend,' 'may,' 'might,' 'plan,' 'potential,' 'possible,' 'will,' 'would,' and other words and terms of similar meaning. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including: our ability to develop, obtain regulatory approval for and commercialize our product candidates; the timing and results of preclinical studies and clinical trials; the risk that positive results in a preclinical study or clinical trial may not be replicated in subsequent trials or success in early stage clinical trials may not be predictive of results in later stage clinical trials; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; the occurrence of adverse safety events; failure to protect and enforce our intellectual property, and other proprietary rights; failure to successfully execute or realize the anticipated benefits of our strategic and growth initiatives; risks relating to technology failures or breaches; our dependence on collaborators and other third parties for the development of product candidates and other aspects of our business, which are outside of our full control; risks associated with current and potential delays, work stoppages, or supply chain disruptions, including due to the imposition of tariffs and other trade barriers; risks associated with current and potential future healthcare reforms; risks relating to attracting and retaining key personnel; changes in or failure to comply with legal and regulatory requirements, including shifting priorities within the U.S. Food and Drug Administration; risks relating to access to capital and credit markets; and the other risks and uncertainties that are detailed under the heading 'Risk Factors' included in BioAge's Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission (SEC) on May 6, 2025, and BioAge's other filings with the SEC filed from time to time. BioAge undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Contacts
PR: Chris Patil, [email protected]
IR: Dov Goldstein, [email protected]
Partnering: [email protected]
Web: https://bioagelabs.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
26-Year-Old New Orleans Police Officer and U.S. Army Reservist Dies from Complications Following BBL Surgery: Reports
A police officer allegedly died after undergoing Brazilian Butt Lift surgery in Miami back in March according to a report from NBC6 South Florida Wildelis Rosa had traveled to Miami for the surgery, and she also celebrated her 26th birthday during the trip Rosa's cause of death was ruled to be pulmonary embolism from blood clots associated with cosmetic surgery, according to NBC6, citing the Miami-Dade Medical Examiner's OfficerA New Orleans police officer and U.S. army reservist died after undergoing Brazilian Butt Lift surgery in Miami back in March according to reports. NBC6 notes that Wildelis Rosa, 26, died on March 23 following the cosmetic procedure, which, per the Cleveland Clinic, sees fat removed from different parts of the body and transferred to the buttocks to increase their size. On March 18, the police officer reportedly arrived in South Florida before having pre-operative blood work the following day at Prestige Plastic Surgery Clinic. According to NBC6, an invoice revealed that Rosa paid $7,495 for the procedure, which saw her bum injected with fat from 12 areas of her body. Rosa then told her family about the procedure three days later, on March 22, with her sister, Anamin Vazquez, revealing to the outlet that she was immediately worried. "We had just that feeling in our guts like something is wrong," she said, adding that she texted her later on March 22, her 26th birthday, but there was "no answer." Rosa died the next day, March 23, after collapsing in the bathroom. A friend who had been staying with her reportedly found her unresponsive and, despite attempting CPR, Rosa passed away. The Miami-Dade Medical Examiner's Office ruled her cause of death to be pulmonary embolism from blood clots associated with cosmetic surgery, NBC6 reported. Vazquez told the outlet that her sister had complained of extreme pain the day after her surgery. She was also allegedly discharged from the hospital just one hour after the procedure. 'She says that…she was having complications,' Vazquez said of a text message Rosa had sent another friend at the time. Paying tribute to her sister, Vazquez says that Rosa had "just come back from a deployment to Kuwait as a U.S. Army Reservist,' adding that she wanted to work for the FBI and had a "very bright and promising future." Vazquez revealed that the family didn't know Rosa, the youngest of five siblings, was going to get cosmetic surgery. She had told them she was going to Miami to celebrate her 26th birthday. Per The Mirror, Vazquez said she wanted her sister's death to be a "cautionary tale for those who are thinking of having these surgeries."Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from juicy celebrity news to compelling human interest stories Back in March, the New Orleans Police Department also paid tribute to Rosa following her death. 'The New Orleans Police Department is heartbroken by the sudden passing of Officer Wildelis Rosa, a cherished member of our NOPD family,' they wrote in a post on Facebook. 'While her passing was not related to active duty, this loss is deeply felt by all who had the privilege of working alongside her.' They added, 'Officer Rosa served with integrity, compassion, and an unwavering commitment to the people of New Orleans.' Her former teacher, Roger, described Rosa as one of the "sweetest, kindest, intelligent, caring, and compassionate people I have ever known," The Mirror notes. PEOPLE has contacted the Prestige Surgery Clinic and the Miami-Dade Medical Examiner's Office for comment but did not immediately hear back. Read the original article on People
Washington Post
an hour ago
- Washington Post
Fecal bacteria forces dozens of beach closures ahead of Fourth of July
Cooling off at a beach or lake is a quintessential part of Fourth of July celebrations for many. But this year, dozens of swimming areas across the country are subject to closures or advisory warnings due to high levels of bacteria, including fecal bacteria, in the water. Bacteria detected include E. coli and enterococci, both used as indicators of fecal matter in water when found at high levels, and which can indicate other disease-causing elements are present, according to the U.S. Environmental Protection Agency.
Yahoo
an hour ago
- Yahoo
‘Cool' people tend to have these six things in common, study finds
An international team of researchers may have just cracked the code for what makes someone 'cool.' And no matter where you live, the personality traits that make someone 'cool' appear to be consistent across countries, according to the study, published this week in the Journal of Experimental Psychology. The researchers found that, compared with people considered to be 'good' or 'favorable,' those considered 'cool' are perceived to be more extroverted, hedonistic, powerful, adventurous, open and autonomous. 'The most surprising thing was seeing that the same attributes emerge in every country,' said Todd Pezzuti, an associate professor of marketing at Universidad Adolfo Ibáñez in Chile who was a co-lead researcher on the study. 'Regardless of whether it's China or Korea or Chile or the US, people like people who are pushing boundaries and sparking change,' he said. 'So I would say that coolness really represents something more fundamental than the actual label of coolness.' The researchers – from Universidad Adolfo Ibáñez, the University of Arizona and the University of Georgia – conducted experiments from 2018 to 2022 with nearly 6,000 people across a dozen countries: Australia, Chile, China, Germany, India, Mexico, Nigeria, Spain, South Africa, South Korea, Turkey and the United States. The participants were asked to think of a person in their lives whom they perceive to be 'cool,' 'uncool,' 'good' or 'not good.' They were then asked to rate that person's personality using two scales: the Big Five Personality scale, a widely used scientific model that helps describe personality traits, and the Portrait Values Questionnaire, intended to measure an individual's basic values. The study participants consistently associated being calm, conscientious, universalistic, agreeable, warm, secure, traditional and conforming with being a good person, more than with being a cool person. Being capable was considered to be both 'cool' and 'good' but not distinctly either. But the formula for being 'cool' was having the six character traits – more extroverted, hedonistic, powerful, adventurous, open and autonomous – no matter the person's age, gender or education level. Pezzuti doesn't think these 'cool' traits are something that can be taught. 'We're born with those attributes,' he said. 'Five of those attributes are personality traits, and personality traits tend to be fairly stable.' The research showed that cool people and good people aren't the same, but there may be some overlapping traits, said co-lead researcher Caleb Warren, an associate professor of marketing at the University of Arizona. 'To be seen as cool, someone usually needs to be somewhat likable or admirable, which makes them similar to good people,' Warren said in a news release. 'However, cool people often have other traits that aren't necessarily considered 'good' in a moral sense, like being hedonistic and powerful.' A limitation of the research was that only people who understood what 'cool' means were included in the study. Pezzuti said it would be interesting – but difficult – to determine whether the findings would be similar among more traditional cultures or remote groups of people who may be less familiar with the term. 'We don't know what we would find in supertraditional cultures like hunting-and-gathering tribes or sustenance farming groups,' Pezzuti said. 'One thing we would propose is that in those cultures, 'cool' people don't have as important of a role because innovation, or cultural innovation, isn't as important in those cultures,' he said. 'So I would say that cool people are probably present in those cultures, but their role isn't as big, and they're probably not as admired as they are in other cultures.' When asked to think of a public figure or celebrity who embodies 'coolness' based on his research, Pezzuti immediately said Tesla and SpaceX CEO Elon Musk. 'He's a controversial figure, but someone who comes to my mind is Elon Musk,' Pezzuti said, adding that he checks all the boxes of the six attributes identified in the study. Musk is 'undeniably powerful' and autonomous, he said, and appears to be extroverted due to his presence on social media platforms and in the media. 'I hear that he's timid, maybe more timid than he seems, but from an outsider, he seems very extroverted. He's entertaining. He's on podcasts and always in front of cameras,' Pezzuti explained. Some of Musk's behavior also appears to be hedonistic, he said. 'He smoked marijuana on the most popular podcast in the world, 'The Joe Rogan Experience.'' And Pezzuti added that Musk's ideas about colonizing Mars show him to be open and adventurous. The new paper is one of the few empirical studies that examines what exactly makes people 'cool,' said Jonah Berger, an associate professor of marketing at the University of Pennsylvania's Wharton School of Business. 'While people have long wondered (and theorized) about what makes people cool, there hasn't been a lot of actual empirical research on the topic, so it's great to see work exploring this space,' Berger, who was not involved in the new paper, wrote in an email. 'While coolness might seem like something you are born with, there are certainly steps people can take to try and move in that direction,' he said. 'Given how many people want to be cool, and how much money is spent with that goal in mind, it certainly seems worth studying.' Future research in this space could evaluate coolness in tandem with goodness and badness rather than in isolation from it, said Jon Freeman, an associate professor of psychology at Columbia University. 'In real life, coolness can be a positive quality but can also have a negative connotation in certain social contexts. It may be valuable for future work to examine the differences between good coolness and bad coolness, and this study's approach offers a great foundation,' Freeman, who also was not involved in the new study, wrote in an email. 'From a scientific standpoint, cool would seem far more a product of inference and social construction than genetics, although low-level temperament informed by genetics could feed into ongoing personality construction,' he said. ''Cool' is deeply ingrained in our social vocabulary because it serves as a shorthand for complex inferences. It encapsulates signals of status, affiliation, and identity in ways that are instantaneous yet deeply stereotyped. From a scientific perspective, studying coolness is important precisely because it reveals how rapid, schematic trait inferences influence behavior and social dynamics, especially in the age of social media and influencer culture.'
